AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03229798
Drug: Sumatriptan Succinate Oral Tablet
RxNorm normalized name: Sumatriptan Succinate
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan succinate commercial Imitrex 100 mg tablet
Trial: NCT01897116
Drug: Vemurafenib (VEM)
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00482833
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28).
Trial: NCT00607035
Drug: Olmesartan medoxomil ＋Azelnidipine
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
Trial: NCT01133613
Drug: Bone morphogenetic protein 7
RxNorm normalized name: Bone morphogenetic protein 7
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Single intraarticular injection of BMP-7 or placebo on Day 1
Trial: NCT00482833
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1.
Trial: NCT00482833
Drug: all-trans retinoic acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed.
Trial: NCT00482833
Drug: all-trans retinoic acid (ATRA)
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26).
Trial: NCT02999217
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay.
Trial: NCT02999217
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay.
Trial: NCT02530151
Drug: Morphine with clonidine
RxNorm normalized name: Clonidine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT00282932
Drug: Detrol LA
RxNorm normalized name: Detrol LA
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03558516
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
Trial: NCT03558516
Drug: Normal saline group
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
Trial: NCT01958970
Drug: PINTA 745
RxNorm normalized name: PENTA
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
Trial: NCT00200460
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00394953
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed, iv.
Trial: NCT00394953
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120, 200 or 360 micrograms iv / month, starting dose
Trial: NCT01614743
Drug: IncobotulinumtoxinA
RxNorm normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Experimental injection given at baseline and Week 16
Trial: NCT01144832
Drug: ebastine
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 milligram capsule once daily
Trial: NCT04069117
Drug: letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: letrozole /antagonist protocol
Trial: NCT03564938
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
Trial: NCT04201951
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
Trial: NCT03613584
Drug: Von Willebrand Factor
RxNorm normalized name: Von Willebrand Factor
DrugBank: Vonicog alfa (DB12872)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
Trial: NCT03613584
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
Trial: NCT02446886
Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors.
Trial: NCT00977054
Drug: DFPP + Peg-IFN + RBV
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
Trial: NCT00977054
Drug: Peg-IFN + RBV
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
Trial: NCT00200434
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04217590
Drug: Sodium Zirconium Cyclosilicate
RxNorm normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
Trial: NCT01034475
Drug: CPI-613
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient \& traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is \>Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme.
Trial: NCT00577161
Drug: fludarabine and rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
Trial: NCT00577161
Drug: fludarabine, rituximab, pixantrone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
Trial: NCT00231387
Drug: rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01419847
Drug: Ciclopirox
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00449423
Drug: acipimox
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00361998
Drug: NITROFURANTOIN MACROCRYSTALS
RxNorm normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02190838
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: per os 850 mg BID
Trial: NCT02190838
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV 1 hour 1000 mg/m\^2 once in 28 days
Trial: NCT02578602
Drug: Gadoxetate Disodium
RxNorm normalized name: Gadoxetate Disodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02387203
Drug: PrevPac (Prevacid, Amoxicillin, Clarithromycin)
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
Trial: NCT04672460
Drug: TALZENNA capsule
RxNorm normalized name: Talzenna
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current commercial talazoparib formulation 1 mg once daily given under fasting condition
Trial: NCT04672460
Drug: Talazoparib soft gel capsule
RxNorm normalized name: talazoparib Oral Capsule
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
Trial: NCT04672460
Drug: Talazoparib soft gel capsule
RxNorm normalized name: talazoparib Oral Capsule
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
Trial: NCT02474186
Drug: Xeloda
RxNorm normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy agent daily for two weeks
Trial: NCT02474186
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy agent weekly for two weeks
Trial: NCT01566656
Drug: total lymphoid irradiation and anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0
Trial: NCT03294109
Drug: Abdominal wall block with liposomal bupivicaine
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abdominal wall block with liposomal bupivicaine
Trial: NCT01876043
Drug: plitidepsin
RxNorm normalized name: plitidepsin
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if \>= 11 non-progressions, Aplidin was considered promising.
Trial: NCT02582203
Drug: Ceftaroline
RxNorm normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02582203
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03597308
Drug: 5mg of Oxycodone every 6 hours as needed for pain
RxNorm normalized name: oxycodone 13.5 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg of Oxycodone every 6 hours as needed for pain
Trial: NCT02331940
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Trial: NCT01525719
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg everolimus
Trial: NCT02821312
Drug: DA-8010
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010.
Trial: NCT02500498
Drug: Nulojix
RxNorm normalized name: Nulojix
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03756389
Drug: BMX-010
RxNorm normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and efficacy of BMX-010 in topical treatment of rosacea.
Trial: NCT01279096
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
Trial: NCT02373813
Drug: etanercept pre-filled syringe subcutaneous injection
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: etanercept for injection in pre-filled syringes
Trial: NCT02373813
Drug: Placebo for etanercept subcutaneous injection
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: etanercept placebo for injection in pre-filled syringes
Trial: NCT00807235
Drug: Aerosolized lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
Trial: NCT00807235
Drug: Aerosolized lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
Trial: NCT02154789
Drug: polidocanol
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01074619
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
Trial: NCT00412971
Drug: Hexvix
DrugBank: Hexaminolevulinate (DB06261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single installation, TURB
Trial: NCT00002566
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002566
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002566
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002566
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03443804
Drug: Reference(Stillen tab.)
RxNorm normalized name: selegiline hydrochloride Oral Tablet [Stilline]
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stillen tab.+Placebo of DW1401
Trial: NCT00002566
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03775746
Drug: Clopidogrel 75Mg Tablet
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
Trial: NCT03775746
Drug: Rivaroxaban 2.5Mg Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)